Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Evaluation of the safety and efficacy of XAV-19 in patients with COVID-19-induced moderate pneumonia: study protocol for a randomized, double-blinded, placebo-controlled phase 2 (2a and 2b) trial.
Gaborit B, Vanhove B, Vibet MA, Le Thuaut A, Lacombe K, Dubee V, Ader F, Ferre V, Vicaut E, Orain J, Le Bras M, Omnes A, Berly L, Jobert A, Morineau-Le Houssine P, Botturi K, Josien R, Flet L, Degauque N, Brouard S, Duvaux O, Poinas A, Raffi F; POLYCOR study group. Gaborit B, et al. Among authors: berly l. Trials. 2021 Mar 9;22(1):199. doi: 10.1186/s13063-021-05132-9. Trials. 2021. PMID: 33750432 Free PMC article.
Pharmacokinetics and Safety of XAV-19, a Swine Glyco-humanized Polyclonal Anti-SARS-CoV-2 Antibody, for COVID-19-Related Moderate Pneumonia: a Randomized, Double-Blind, Placebo-Controlled, Phase IIa Study.
Gaborit B, Dailly E, Vanhove B, Josien R, Lacombe K, Dubee V, Ferre V, Brouard S, Ader F, Vibet MA, Le Thuaut A, Danger R, Flet L, Omnes A, Berly L, Chiffoleau A, Jobert A, Duvaux O, Raffi F; POLYCOR Trial Group. Gaborit B, et al. Among authors: berly l. Antimicrob Agents Chemother. 2021 Aug 17;65(9):e0123721. doi: 10.1128/AAC.01237-21. Epub 2021 Aug 17. Antimicrob Agents Chemother. 2021. PMID: 34181475 Free PMC article. Clinical Trial.
How many patients are eligible for disease-modifying treatment in Alzheimer's disease? A French national observational study over 5 years.
Epelbaum S, Paquet C, Hugon J, Dumurgier J, Wallon D, Hannequin D, Jonveaux T, Besozzi A, Pouponneau S, Hommet C, Blanc F, Berly L, Julian A, Paccalin M, Pasquier F, Bellet J, Boutoleau-Bretonniere C, Charriau T, Rouaud O, Madec O, Mouton A, David R, Bekadar S, Fabre R, Liegey E, Deberdt W, Robert P, Dubois B. Epelbaum S, et al. Among authors: berly l. BMJ Open. 2019 Jun 24;9(6):e029663. doi: 10.1136/bmjopen-2019-029663. BMJ Open. 2019. PMID: 31239309 Free PMC article.
Lyme neuroborreliosis and dementia.
Blanc F, Philippi N, Cretin B, Kleitz C, Berly L, Jung B, Kremer S, Namer IJ, Sellal F, Jaulhac B, de Seze J. Blanc F, et al. Among authors: berly l. J Alzheimers Dis. 2014;41(4):1087-93. doi: 10.3233/JAD-130446. J Alzheimers Dis. 2014. PMID: 24762944
Insular cognitive impairment at the early stage of dementia with Lewy bodies: a preliminary study.
Philippi N, Kemp J, Constans-Erbs M, Hamdaoui M, Monjoin L, Ehrhard E, Albasser T, Botzung A, Demuynck C, Heim G, Martin-Hunyadi C, Bilger M, Berly L, Soulier D, Cretin B, Després O, Blanc F. Philippi N, et al. Among authors: berly l. Geriatr Psychol Neuropsychiatr Vieil. 2017 Sep 1;15(3):329-338. doi: 10.1684/pnv.2017.0684. Geriatr Psychol Neuropsychiatr Vieil. 2017. PMID: 28872044 English.